Global Blood Coagulants Market Research Report: Information by Type (Coagulation Factor (Recombinant Coagulation Factor & Plasma-Derived Coagulation Factor) & Others), & Indication (Hemophilia, Surgery, & Other Bleeding Disorders)—Forecast till 2023
It is estimated that the global blood coagulants market is expected to register a CAGR ~ 11.5% with an estimated market value of USD 720.7 million during the forecast period of 2018–2023.
The global market is driven by factors such as increased bleeding disorders, the rise in the research activities, and an increase in the healthcare project grants provided by public and private organizations, among others. Additionally. The growing awareness created by various non-profit organizations, as well as government campaigns help to drive the growth of the market. For instance, the World Federation of Hemophilia (WFH) launched a Development Grant Program (DGP) in 2018 to encourage innovative ideas and projects to support the inherited bleeding disorders community globally.
Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/7632
Moreover, key companies are actively involved in spreading awareness. For instance, in April 2018, CSL Behring shipped more than 10 million international units (IUs) of its medicines to treat hemophilia A to developing countries through the non-profit World Federation of Hemophilia (WFH) on account of World Hemophilia Day on April 17. The medicines were sent to countries like Vietnam, Cameroon, and others through the WFH’s Global Alliance for Progress (GAP) Program, which seeks to improve the diagnosis and treatment of bleeding disorders in developing countries.
On the other hand, the lack of awareness regarding blood clotting and its severity, the high cost of diagnostic tests in some economies, and the rising counterfeit drugs are restraining the growth of blood coagulants market. For instance, according to the statistics published by the National Hemophilia Foundation, annually 75% of hemophilic people worldwide receive inadequate treatment or have no access to treatment.
The global blood coagulants market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic collaborations to strengthen its market position. For instance, For instance, in May 2016, CSL Behring announced the US FDA approval of AFSTYLA, a recombinant factor VIII Single Chain Therapy for Hemophilia A.
The market in the Americas is expected to dominate the global blood coagulants market during the forecast period owing to the increasing per capita healthcare expenditure, increase in product innovation, and heavy adoption of new technology in the region. Europe is expected to hold the second largest position in the global blood coagulants market. The market growth in this region is because of the presence of a well-established healthcare system. The increase in marketing approvals and authorizations in the region also propels the growth of the market. For instance, in June 2018, Octapharma announced that the European Medicines Agency (EMA) had approved an extension of marketing authorization for its product, Nuwiq, a human cell line-derived recombinant factor VIII (rFVIII) for the treatment in patients with hemophilia A.
Asia-Pacific is estimated to be the fastest growing region in the market due to the increasing number of welfare programs, coupled with the substantial generation of disposable income. Additionally, the increase in people suffering from bleeding disorders drives the growth of the market. According to the statistics published by Hemophilia Foundation Australia, Von Willebrand Disease (VWD), an inherited bleeding disorder affects approximately 200,000 people annually in Australia. The market in the Middle East & Africa is likely to account for the smallest share of the global blood coagulants market. This owes to the poor access to treatment, and limited screening and diagnostic services in the region.
The global blood coagulants market has been segmented into type and indication. The market, based on type, has been segmented into coagulation factor and others. The market, by coagulation factor, has been further segmented into recombinant coagulation factor and plasma-derived coagulation factor. The market, by indication, has been sub-segmented into hemophilia, surgery, and other bleeding disorders.
Some of the key players in the global blood coagulants market are Novo Nordisk A/S, Aptevo Biotherapeutics LLC, Baxalta US Inc., Baxter Laboratories, Bayer AG, CSL Behring, GRIFOLS USA, LLC, Octapharma, Pfizer, Shire, and SOBI.
Access Report Details @ https://www.marketresearchfuture.com/reports/global-blood-coagulants-market-7632
The report for Global market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Government Research Institutes
- Academic Institutes and Universities
- Venture Capitalists
- Report Prologue
2. Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
3. Research Methodology
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Ask Questions to Expertise @ https://www.marketresearchfuture.com/enquiry/7632
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312